Revvity Hits New High on Diabetes Test but Growth Lags

• Our read: EasyAlpha grades Revvity Inc. D, indicating below-average quality compared to Healthcare peers in the S&P 500. Solid earnings quality contrasts with weak growth, while the stock trades 14.7% above Wall Street price targets despite lukewarm analyst ratings.
• The day: Shares gained 6.0% to close at $150.68, touching a fresh annual high after the company rolled out an early diabetes screening test in Europe.
• Watching: Third-quarter earnings results scheduled for Monday, October 26.

Revvity shares jumped 6.0% on Thursday, September 24 to finish at $150.68, marking the stock's sixth-largest single-day gain over the past year and eclipsing its prior peak of $149.52. Trading volume reached 1.2x the daily average as market participants responded to commercial news from the company's diagnostics business.

The catalyst arrived from Europe, where Revvity announced the commercial debut of its GSP T1D 3plex kit, an automated diagnostic designed to screen newborns and young children for type 1 diabetes risk before physical symptoms appear. The test holds CE-IVDR certification and runs on the company's genetic screening processor platform using dried blood spot samples, aiming to identify autoantibodies before extensive pancreatic beta-cell destruction occurs. The rollout generated widespread midday interest as traders evaluated the addition to Revvity's neonatal screening and immunodiagnostics catalog.

While the diagnostic rollout provided immediate trading momentum, EasyAlpha grades Revvity Inc. D, placing it in the below-average quality tier among Healthcare companies in the S&P 500. Companies graded D or E have historically carried a higher risk of large drawdowns than companies in the top tiers. Although Revvity demonstrates sound earnings quality, its profile is weighed down by sluggish growth. Quarterly revenue growth was +1.3% year over year, a subdued pace that stands in sharp contrast to the stock's rapid price appreciation.

That extended rally has stretched valuation multiples. Revvity is +55.7% so far this year, lifting the price well above its prior trading range. The stock currently trades at 68.9 times trailing earnings and 24.4 times forward earnings, supported by a return on equity of 3.2% and steady profit generation.

Wall Street analysts have maintained a cautious view of the run. Only 35.3% of the 17 analysts covering the stock rate it as a buy, with an average price target of $128.47. Thursday's closing price left the stock 14.7% above that consensus target.